Using AI, deep learning to fight aging

A Baltimore-based company is utilizing the power of artificial intelligence (AI) and deep learning to advance drug discovery, biomarker development and aging research.

Leveraging advanced AI, Insilico Medicine aims to use bioinformatics, research and development to extend patient lives.

“You have to look at the number of quality years of life you’re adding. If you include every individual on the planet, and you are adding one year of quality life to each of them, you’re generating 7.5 billion quality-adjusted life years,” said founder and CEO Alex Zhavoronkov, PhD. “That is the most altruistic decision to make. So if you go after aging, you are affecting the quality of life for everyone on the planet. The benefit of aging research generates the most benefit to society as a whole. If I can personally give one year of quality life to everyone, my life was very well spent.”

Read the full story from Forbes below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

While Kardium raised $250 million in an oversubscribed funding round, Field Medical raised $35 million. Both companies are focused on designing and developing new pulsed field ablation technologies to help treat challenging arrhythmias. 

Johnson & Johnson MedTech has received reports of its Automated Impella Controller failing to connect properly with Impella heart pumps. If this happens, the FDA warned, it may put patients at risk.

Vascular Technology, first founded 40 years ago, is planning on using the new funds to grow and expand its portfolio.